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Not all bases in the human genome are equally prone to chance mutations. Michaelson et al. show
that individuals can acquire clusters of de novo DNA changes and propose that the likelihood of
single base pair change differs across three orders of magnitude.The replication or maintenance of human
genomes through cell lineages or across
generations is not always completely
faithful. Rare mutations accumulate
whose eventual fate is to be lost through
drift or negative selection or to be fixed
in our future population. Although these
mutations are random, in the sense that
when or where they occur is highly unpre-
dictable, not all base pairs stand an even
chance of being mutated, and conse-
quently, there are regions of the human
genome that are hotspots, or coldspots,
of change. Pinpointing these hotspots
might lead to a better understanding of
both mutational mechanisms and the
frequency by which spontaneous se-
quence change causes noninherited
genetic disease. In this issue of Cell,
Michaelson et al. (2012) identify de novo
germline mutations in monozygotic twins
who are concordant for autism and
propose that mutational variation is
largely explained by intrinsic characteris-
tics of DNA sequence and chromatin
structure.
The authors deep-sequenced immor-
talized lymphoblastoid cell line genomes
from ten pairs of monozygotic twins with
autism and from their parents. On
average, 58 DNA changes were present
in both twins, yet were absent from their
parents, and thus were likely to have
arisen de novo in their common germline
genome, rather than being somatic or
cell linemutations. This number translates
to an average human genome-widemuta-
tion rate of 1 3 108 per base pair per
generation, similar to previous estimates
(Conrad et al., 2011; Campbell et al.,
2012; Kong et al., 2012; Sun et al.,
2012). Michaelson et al. (2012) then
show that the majority of these DNA
changes were of paternal origin. This isconsistent with mutations being predom-
inantly replication-dependent, having
been introduced during the greater
number of germline cell divisions in the
life history of a sperm relative to that of
an egg (Crow, 2000; Veltman and Brun-
ner, 2012; see also Kong et al., 2012).
They show that each additional year for
fathers between the ages of about 28
and 40 introduces, on average, one de
novo mutation to his off-spring’s genome.
These de novo mutations failed to fall
evenly across the genome and some lay
within even very short chromosomal
regions. Six <100 bp regions contained
two or three such mutations linked to the
same individual, indicating that these
were introduced either as compound
heterozygous mutations, in cis simulta-
neously, or through successive events of
gene conversion (see also Campbell
et al., 2012).
Michaelson et al. (2012) then use
logistic regression to show that de novo
mutations were unexpectedly frequent at
the small scale (<100 bp) in three
sequence classes: simple repeats, DNase
1 hypersensitivity sites from embryonic
stem cells, and various trinucleotide
sequences. The known high rate of repli-
cation slippage in simple repeats likely
accounts for the first enrichment. The
high mutation rate in DNase 1 hypersensi-
tivity sites is, however, unexpected (Pre-
ndergast et al., 2007) but could reflect
substantial differences in open chromatin
regions between embryonic stem cells
and male germ cells. By far the greatest
enrichment is that for trinucleotide se-
quences. In great part, this is explained
by the high mutability of the CpG dinucle-
otide and, to a lesser extent, of the
CpNpG trinucleotide arising mostly from
the spontaneous deamination of 5mCCell 151, De(Cooper et al., 2011). Michaelson et al.
(2012) found that 15% of their de novo
mutations were of the CpG type, a similar
proportion to that observed by others
(Conrad et al., 2011 [13%]; Campbell
et al., 2012 [17%]; Kong et al., 2012
[19%]).
By constructing principal components
from a set of 78 quantitative and se-
quence features of the genome at
different linear scales, the authors then
define a mutability index (MI) for all sites
across the human genome. This index is
the log10 value of the fold-excess of de
novo mutations expected from these
features; hence, if all sites were equally
mutable then they would be associated
with MI values of zero. As expected, the
majority of CpG sites have high MI values,
exceeding 0.5, which is about a 3-fold
enrichment of mutations (Figure 1). Inter-
estingly, the authors predict exonic
sequence to be on average 30% more
prone to mutation than the genome as
a whole, in part perhaps because coding
sequence is G+C and CpG-rich. Genes
associated with recessive or dominant
disease were predicted to show even
greater tendencies for being mutated, at
approximately 35% and 40% average
increases, respectively, results that are
in agreement with a previous cross-
species comparison (Huang et al., 2004).
These findings imply that features of
such disease genes make them slightly
more susceptible to being mutated or to
their mutations being repaired less effi-
ciently in germline cells.
Somewhat counterintuitively, protein-
coding sequence that has been better
conserved, either within or between
species, was predicted to be modestly
(up to 70%) more prone to mutation.
This implies that deleterious variants arecember 21, 2012 ª2012 Elsevier Inc. 1399
Figure 1. Genomic Features and Mutability
Schematic representation of the range of estimated mutability index (MI) values (x axis) for exon (green),
non-CpG (red) and CpG (blue) sequences. The null expectation—that assumes all sequence to be equally
mutable—would yield MI = 0 values (black line). Exonic sequence tends to have slightly higher MI values
than this expectation, and exons from a set of 93 genes that have been implicated in ASD (‘‘ASD Exons’’)
tend to have a further modest increase in mutability. Median MI values for exon and ASD gene exon
sequences are indicated by green and purple arrows, respectively.more frequently purged from particular
classes of protein-coding sequence not
just because of their greater effects on
fitness but also because they arise,
through mutation, more frequently. Over-
all, these results imply that sequence
within genes that contributes to funda-
mental biological processes is particularly
prone to beingmutated and through these
mutations to contribute to disease.
The Michaelson et al. (2012) study
reveals how the mutation rate can vary
over three orders of magnitude across
the human genome and how CpG-rich
or exonic sequence is mutated more
frequently. Nevertheless, predicted MI
values are not sufficiently accurate to reli-
ably estimate mutation rates at single
sites, and MI values could not be used1400 Cell 151, December 21, 2012 ª2012 Elsto distinguish a cohort of individuals with
autism spectrum disorders (ASD) from
healthy individuals. The study’s identifica-
tion of 29 protein-coding genes that
contained de novo mutations (of which
only ten were exonic) did, however, shed
some light on these disorders. For ex-
ample, two genes, KIRREL2 and GPR98,
mutated in an ASD cohort were also
mutated in individuals in a replication
cohort, thereby elevating their status as
excellent ASD candidate genes.
Michaelson et al.’s observations of
paternal bias and mutational hotspots in
the human genome extend and confirm
results from other recent studies (Conrad
et al., 2011; Campbell et al., 2012; Kong
et al., 2012; Sun et al., 2012). Together
these publications demonstrate howevier Inc.whole-genome sequencing within fami-
lies has now become sufficiently accurate
to catalog an individual’s unique set of
mutations. Nevertheless, given the extent
and variety of mutations they uncovered,
these studies highlight the substantial
challenges ahead in accurately explaining
traits or disorders in terms of de novo
variants.
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